1
## **Erase Meso Annual Report period ending 31[st] December 2023**
## **Registered Charity Number: 1183208 Registered Address: 4 Capern Road, London SW18 3EE**
## **Trustees During 2023**
Paul Cook Appointed 1[st] May 2019 Richard Bath Appointed 1[st] May 2019 Wayne O’Neil Appointed 1[st] May 2019
## **Objectives**
The objects of Erase Meso (EM) are to promote and protect the physical and mental health of existing and future sufferers of Mesothelioma throughout the world through:
1. Provision of financial assistance to scientific research aimed at finding a cure for Mesothelioma and/or controlling the non-financial impact of the disease on existing and future sufferers.
2. Advancement of education and awareness of the general public in all areas relating to Mesothelioma.
## **Governance**
EM is a Charitable Incorporated Organisation, established on 1[st] May 2019, and operating according to a Constitution based on the ‘foundation’ model.
The charity trustees, listed above, make all key decisions and are the only voting members of the Organisation.
The trustees meet regularly to discuss both operational activities of EM and strategic initiatives and direction.
2
## **Events and Activities**
During 2023 the Trustees continued the process for establishing a Research Advisory Board to aid with the identification and selection of research projects to fund in line with the EM’s charity’s objectives.
In addition, Erase Meso contributed £37,973 for a research grant administered by Mesothelioma UK (Charity No. 1177039) and continued to efforts to build partnerships with related charities.
Minimal fundraising events and activities took place in 2023, with £5,040 received in donations.
## **Accounts**
EM prepare accounts on a receipts and payments basis in line with Charities Commissions requirements.
For the period 1[st] January 2023 to 31[st] December 2023 funds of £5,040 were raised from events and donations.
Payments of £39,465 were deducted, predominantly from £37,973 of grant funding for research into Mesothelioma. The remaining payments of £1,492 related to liability insurance, IT licences and fees deducted by payment and fundraising platforms. EM operates on a volunteer basis, and as such no payments were made for management or advisory services during 2023.
Overall excess of payments over receipts was £34,426, reducing cash and equivalents held at balance date.
## **Other**
The Trustees would like to express our sincere gratitude to all who have supported EM in our endeavour to raise funds for scientific research and to raise awareness of mesothelioma.
Signed on behalf of the Trustees
Paul Cook (Trustee)
Richard Bath (Trustee)
**1183208**
**Erase Meso**
## **Recei ts and a ments accounts p p y**
**CC16a**
|**For the period**
**from**|1st January 2023|**To**|31st December|
|---|---|---|---|
## **Section A Receipts and payments**
|**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest £**
**5,040**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**5,040**
**-**
**-**
**-**
**5,040**
**1,492**
**37,973**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**39,465**
**-**
**-**
**-**
**39,465**
**- 34,425**
**-**
**203,369**
**168,944**|**Restricted**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Restricted**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Endowment**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Endowment**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Total funds**
**to the nearest £**
**5,040**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**5,040**|**Total funds**
**to the nearest £**
**5,040**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**5,040**|**Last year**
**to the nearest £**|
|---|---|---|---|---|---|---|---|---|
|Donations|**5,040**|||||||**19,024**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
|**_Sub total_**_(Gross income for_
_AR)_|
**5,040**|||||||**19,024**|
||||||||||
|**A2 Asset and investment sales,**
**(see table).**|||||||||
||**-**|**-**||**-**||**-**|||
||**-**|**-**||**-**||**-**||**-**|
|~~**_Sub total_**~~|**-**|**-**||**-**||**-**||**-**|
|**_Total receipts_**
**A3 Payments**|||||||||
|||||||||**19,024**|
||||||||||
|Admin expenses|**1,492**|||||||**1,793**|
|Grants|**37,973**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
||**-**|||||||**-**|
|**_Sub total_ **|**39,465**|||||||**1,793**|
||||||||||
|**A4 Asset and investment**
**purchases, (see table)**|||||||||
||**-**||||||||
||**-**||||||||
|**_Sub total_ **|**-**|||||||**-**|
|**_Total payments_**
**_Net of receipts/(payments)_**
**A5 Transfers between funds**
**A6 Cash funds last year end**
**_Cash funds this year end_**|||||||||
|||||||||**1,793**|
||||||||||
||**- 34,425**|**-**||||**- 34,425**||**17,231**|
||**-**|**-**||||**-**||**-**|
||**203,369**|**-**||||**203,370**||**-**|
||**168,944**|**-**||||**Cross Add Error**||**17,231**|
|**Section B Statement of assets and liabilities at**|**Section B Statement of assets and liabilities at**|**the end of the period**|**the end of the period**||
|---|---|---|---|---|
|**Categories**
**B1 Cash funds**
CCXX R1 accounts (SS)|Bank accounts & Equivelents
**Details**
1|**Unrestricted**
**funds**
**to nearest £**
**168,944**|**Restricted**
**funds**
**to nearest £**
**-**|**Endowment**
**funds**
**to nearest £**|
||Bank accounts & Equivelents
1|**168,944**|**-**|**-**
31/10/2024|
|Signed by one or two trustees on
behalf of all the trustees
**B2 Other monetary assets**
**B4 Assets retained for the**
**charity’s own use**
**B5 Liabilities**
**B3 Investment assets**|||||||**-**|
|---|---|---|---|---|---|---|---|
||||||||**-**|
||||||||**-**|
||||||||OK|
||||||||**Endowment**
**funds**
**to nearest £**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**Current value**
**(optional)**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**-**|
||||||||**Current value**
**(optional)**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||||||**-**||**-**|
||**Details**||**Fund to which**
**liability relates**||**Amount due**
**(optional)**||**When due**
**(optional)**|
||||||**-**|||
||||||**-**|||
||||||**-**|||
||||||**-**|||
||||||**-**|||
||Signature||Print Name
Richard Bath|||||
||||||||Date of
approval|
||||Richard Bath||||31/10/2024|
|||||||||
CCXX R2 accounts (SS)
31/10/2024
2